SCHEMBL7550083

SCHEMBL7550083

O=C(O)c1cc(O)ccc1-c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 1.00
SMN1; SMN2 Q16637 1/20 0.58
CA12 O43570 3/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
CA14 Q9ULX7 2/20 0.57
ALOX5 P09917 2/20 0.57
PTGS2 P35354 1/20 0.57
ALDH1A1 P00352 1/20 0.52
TSHR P16473 1/20 0.52
FOLH1 Q04609 2/20 0.49
POLB P06746 2/20 0.47
ESR2 Q92731 2/20 0.46
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
HSD17B1 P14061 1/20 0.44
ALPL P05186 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29737473 1.00 HSD17B10 (1.00) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL699045 0.90 HSD17B10 (0.81) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL3814907 0.89 HSD17B10 (0.79) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL10079022 0.89 HSD17B10 (0.79) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL7262126 0.87 HSD17B10 (0.76) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL30387687 0.87 HSD17B10 (0.76) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL30013531 0.87 HSD17B10 (0.76) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL2788717 0.86 HSD17B10 (0.76) HSD17B10SMN1; SMN2CA12CA1CA2
SCHEMBL20488085 0.85 HSD17B10 (0.73) HSD17B10SMN1; SMN2CA12CA1CA2
Biphenyl SCHEMBL976757 0.84 HSD17B10 (0.72) HSD17B10ALOX5ALDH1A1FOLH1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3142777-B1 COMPOSITE POLYAMIDE MEMBRANE POST TREATED WITH NITROUS ACID DOW GLOBAL TECHNOLOGIES LLC (US) 2018-10-24 EP disclosed
EP-3092057-B1 TREATMENT OF AQUEOUS MIXTURES CONTAINING ANIONIC SURFACTANTS USING FOULING RESISTANT REVERSE OSMOSIS MEMBRANE DOW GLOBAL TECHNOLOGIES LLC (US) 2018-09-19 EP disclosed
EP-3092056-B1 DESALINATION OF AQUEOUS MIXTURE CONTAINING NANO-SIZED PARTICLES USING FOULING RESISTANT REVERSE OSMOSIS MEMBRANE DOW GLOBAL TECHNOLOGIES LLC (US) 2018-08-01 EP disclosed
EP-3077088-B1 METHOD FOR FORMING A COMPOSITE POLYAMIDE MEMBRANE POST TREATED WITH NITRIOUS ACID DOW GLOBAL TECHNOLOGIES LLC (US) 2017-12-27 EP disclosed
US-9808769-B2 Composite polyamide membrane post treated with nitrious acid DOW GLOBAL TECHNOLOGIES LLC (US) 2017-11-07 US disclosed
EP-3142777-A1 COMPOSITE POLYAMIDE MEMBRANE POST TREATED WITH NITROUS ACID Dow Global Technologies LLC (US) 2017-03-22 EP disclosed
US-20170050152-A1 COMPOSITE POLYAMIDE MEMBRANE POST TREATED WITH NITROUS ACID DOW GLOBAL TECHNOLOGIES LLC (US) 2017-02-23 US disclosed
EP-3092057-A1 TREATMENT OF AQUEOUS MIXTURES CONTAINING ANIONIC SURFACTANTS USING FOULING RESISTANT REVERSE OSMOSIS MEMBRANE Dow Global Technologies LLC (US) 2016-11-16 EP disclosed
EP-3092056-A1 DESALINATION OF AQUEOUS MIXTURE CONTAINING NANO-SIZED PARTICLES USING FOULING RESISTANT REVERSE OSMOSIS MEMBRANE Dow Global Technologies LLC (US) 2016-11-16 EP disclosed
US-20160303516-A1 DESALINATION OF AQUEOUS MIXTURE CONTAINING NANO-SIZED PARTICLES USING FOULING RESISTANT REVERSE OSMOSIS MEMBRANE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-10-20 US disclosed
US-20150065542-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2015-03-05 US disclosed
US-20140364617-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2014-12-11 US disclosed
US-20140364617-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2014-12-11 US disclosed
WO-2012083053-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
EP-0968310-B1 NOVEL PHENOL CONDENSATION PRODUCTS BAYER AG (DE) 2002-06-26 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
US-4927903-A ESTERIFICATION OF POLYCARBONATE BAYER AKTIENGESELLSCHAFT (DE) 1990-05-22 US disclosed
EP-0127842-B1 DIPHENOL MONOESTERS OF CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE IN THE PREPARATION OF POLYESTER CARBONATES, POLYESTER CARBONATES OBTAINED ACCORDING TO THE INVENTION AND FLAME-RETARDANT MOULDING COMPOUNDS CONTAINING THESE POLYESTER CARBONATES BAYER AG (DE) 1986-07-02 EP disclosed
EP-0127842-A1 Diphenol monoesters of carboxylic acids, process for their preparation, their use in the preparation of polyester carbonates, polyester carbonates obtained according to the invention and flame-retardant moulding compounds containing these polyester carbonates BAYER AG (DE) 1984-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364617-A1 ANTI-VIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS HSD17B10 1774/4885SMN1; SMN2 3721/4885CA12 3463/4885
US-20150065542-A1 ANTI-VIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS HSD17B10 1774/4885SMN1; SMN2 3721/4885CA12 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.